Share on StockTwits

Cytomedix (NASDAQ:CMXI) CEO Martin P. Rosendale acquired 25,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average cost of $0.40 per share, with a total value of $10,000.00. Following the completion of the purchase, the chief executive officer now directly owns 229,149 shares of the company’s stock, valued at approximately $91,660. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cytomedix (NASDAQ:CMXI) traded up 2.63% on Monday, hitting $0.39. 15,000 shares of the company’s stock traded hands. Cytomedix has a one year low of $0.33 and a one year high of $0.68. The stock has a 50-day moving average of $0.39 and a 200-day moving average of $0.47. The company’s market cap is $48.5 million.

Cytomedix, Inc is a United States-based company that develops biologically active regenerative therapies for wound and tissue repair.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.